Neuland Laboratories
| NSE: NEULANDLAB BSE : 524558 | |
| Company type | Public |
| Industry | CDMO |
| Founded | January 7 1984 |
| Headquarters | , |
Area served | North America, Switzerland, UK, Germany, Italy and the Netherlands and 80 more countries. |
Key people | Dr. Davuluri Rama Mohan Rao (Executive Chairman) D. Sucheth Rao (Vice Chairman & Chief Executive Officer) D. Saharsh Rao (Vice Chairman & Managing Director) |
Number of employees | 1700+ (including 180 Scientists) |
Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) headquartered in Hyderabad.[1] Founded in 1984, the company produces active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs.[2] Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange.[3][4]
Product development
The company's operations are divided into three segments: Custom Manufacturing Solutions, which develops APIs from pre-clinical to commercial stages; Generic Drug Substances, which manufactures non-exclusive APIs; and a Peptide API unit that specializes in peptide synthesis.[5]
References
- ^ "Buy, Sell or Hold: Nuvama initiates coverage on Neuland Laboratories; Motilal Oswal maintains buy on L&T Finance". The Economic Times. Retrieved 2025-10-06.
- ^ "Market master Vijay Kedia's 2 favourite stocks: Must-know holdings for smart investors". Financialexpress. 12 May 2025.
- ^ Laboratories, Neuland. "Why Neuland Laboratories shares fall 7% in trade? check reasons here". www.business-standard.com.
- ^ "Neuland appoints Parag Deshmukh as SVP – Head of Manufacturing". www.indianpharmapost.com/.
- ^ "Neuland Laboratories". HDFC securities.